Overview

A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and safety of DHP107 (Oral paclitaxel) in comparison to Taxol®(IV paclitaxel) in Patients With Metastatic or Recurrent Gastric Cancer After Failure of 1st Line Chemotherapy With Fluoropyrimidine +/- Platinum.

Phase:

Phase 3

Details

Lead Sponsor:

Daehwa Pharmaceutical Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel